RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on May 6, 2024. They announced that they would report on Monday.
BioCryst management will host a conference call and webcast on the same day at 8:30 a.m. ET to discuss financial results and provide an update on the company.
Live calls can be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the conference call will be available online in the Investor section of the Company's website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company deeply committed to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class and best-in-class oral small molecule and protein therapeutics that target difficult-to-treat diseases. BioCryst commercializes ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and advances its pipeline of small molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
contact:
john bruce
+1 919 859 7910
jbluth@biocryst.com
